Home › Trial NCT05512481
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
- Trial IDNCT05512481
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorPeking University Cancer Hospital & Institute
- Enrollment60
- Start date2022-09-13
- ConditionsMelanoma · Acral Melanoma · Temozolomide · Apatinib · Camrelizumab · Neoadjuvant
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.